...the OptiNose bidirectional nasal delivery device, in Phase II testing for autism. Novartis AG markets Syntocinon...

...it also is developing the drug to treat rage disorders in autism. Its pipeline includes Syntocinon...

...Last month, Novartis AG (NYSE:NVS; SIX:NOVN) granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...

...up $2.99 (35%) to $10.49 on Friday Retrophin submitted an application to FDA to reintroduce Syntocinon...
...Last month, Novartis AG (NYSE:NVS; SIX:NOVN) granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...
...for commercial reasons in 1997. Novartis still markets the product in Europe and other countries. Syntocinon...

...granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon oxytocin nasal spray. Novartis discontinued Syntocinon...

...be reached for comment. Separately, Novartis granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...
...plans to reintroduce the product in the U.S. in 2Q14 and conduct clinical trials for Syntocinon...
...controlled studies to confirm findings of improvement in patients with schizophrenia and autism. Novartis discontinued Syntocinon...